Key points from article :
Cambrian Biopharma formed Tornado Therapeutics to develop rapamycin analogues (rapalogs).
Rapamycin is better validated than any other therapeutic for targeting aging and extending lifespan, says Joan Mannick, CEO of Tornado.
People are keen to start taking rapamycin, but things like dose and duration are still unclear.
“How should they be used? What dose? What duration? What indications? What population?.”
“We need new rapalogs, with an IP runway, to determine what benefits rapalogs have for humans,” - Mannick.
“There are 82 different flavours of rapalogs, each with slightly different biology and improved efficacy for specific indications.”
Tornado is now in the process of testing its compounds in different preclinical disease models.
One compound is already on a path to clinical trial (to begin in 12-24 months), and another in preclinical efficacy testing.
Mannick’s previous experience at Novartis and resTORbio will provide Tornado with some key insight.
